Sobi, Inc.
Clinical trials sponsored by Sobi, Inc., explained in plain language.
-
New hope for kids with low platelets: drug shows promise in controlling bleeding risk
Disease control CompletedThis study tested a drug called avatrombopag in 75 children aged 1 to 17 with immune thrombocytopenia (ITP) for at least 6 months. The goal was to see if it could safely raise platelet counts to reduce bleeding risk. Children took the drug or a placebo for 12 weeks, and some cont…
Phase: PHASE3 • Sponsor: Sobi, Inc. • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for low platelet counts: avatrombopag trial shows promise in chronic ITP
Disease control CompletedThis study tested a drug called avatrombopag in 19 Japanese adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants took the drug for 26 weeks to see if it could safely increase platelet counts…
Phase: PHASE3 • Sponsor: Sobi, Inc. • Aim: Disease control
Last updated May 20, 2026 11:57 UTC